Shorter leukocyte telomere length is associated with adverse COVID-19 outcomes: A cohort study in UK Biobank

Qingning Wang, PhD,^{1,2}, Veryan Codd, PhD,^{1,2}, Zahra Raisi-Estabragh, MD,^{3,4}, Crispin Musicha, PhD,^{11,2}, Vasiliki Bountziouka, PhD,^{11,2}, Stephen Kaptoge, PhD,^{15,6,7}, Elias Allara,MD,^{5,6}, Emanuele Di Angelantonio, MD,^{5,6,7,8}, Adam S. Butterworth, PhD,^{5,6,7,8}, Angela M. Wood, PhD,^{5,6,7,8,9,10}, John R. Thompson, PhD,¹¹, Steffen E, Petersen, MD,^{3,4}, Nicholas C. Harvey, PhD,^{12,13}, John N. Danesh, FMedSci,^{5,6,7,8,14}, Nilesh J. Samani,FMedSci,^{1,2}, Christopher P. Nelson, PhD^{1,2,†}

- 1. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
- 2. NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
- 3. William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK;
- 4. Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, EC1A 7BE, London, UK
- 5. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
- 6. National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK.
- 7. British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK.
- 8. Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
- 9. Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK
- 10. The Alan Turing Institute, London, UK
- 11. Department of Health Sciences, University of Leicester, UK
- 12. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK;
- 13. NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK
- 14. Department of Human Genetics, Wellcome Sanger Institute, Hinxton, United Kingdom
- + Corresponding author

Corresponding author

Christopher P. Nelson, <u>chris.p.nelson@leicester.ac.uk</u>, phone +44 (0)116 204 4745, address Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK

Abstract (word count=250)

Background: Older age is the most powerful risk factor for adverse coronavirus disease-19 (COVID-19) outcomes. It is uncertain whether leucocyte telomere length (LTL), previously proposed as a marker of biological age, is also associated with COVID-19 outcomes.

Methods: We associated LTL values obtained from participants recruited into UK Biobank (UKB) during 2006-2010 with adverse COVID-19 outcomes recorded by 30 November 2020, defined as a composite of any of the following: hospital admission, need for critical care, respiratory support, or mortality. Using information on 130 LTL-associated genetic variants, we conducted exploratory Mendelian randomisation (MR) analyses in UKB to evaluate whether observational associations might reflect cause-and-effect relationships.

Findings: Of 6,775 participants in UKB who tested positive for infection with SARS-CoV-2 in the community, there were 914 (13.5%) with adverse COVID-19 outcomes. The odds ratio (OR) for adverse COVID-19 outcomes was 1.17 (95% Cl 1.05-1.30; P=0.004) per 1.SD shorter usual LTL, after adjustment for age, sex and ethnicity. Similar ORs were observed in analyses that: adjusted for additional risk factors; disaggregated the composite outcome and reduced the scope for selection or collider bias. In MR analyses, the OR for adverse COVID-19 outcomes was directionally concordant but non-significant.

Interpretation: Shorter LTL is associated with higher risk of adverse COVID-19 outcomes, independent of several major risk factors for COVID-19 including age. Further data are needed to determine whether this association reflects causality.

Funding: UK Medical Research Council, Biotechnology and Biological Sciences Research Council and British Heart Foundation.

Research in context

Evidence before this study:

We searched PubMed for articles with the terms "telomere length" and "COVID-19" to identify publications relating to telomere length and COVID-19 outcomes. We retained only research articles that used telomere length as a biomarker, identifying three articles. All of these studies showed a relationship between shorter telomere length and either COVID-19 severity or outcome. However, all had measured leucocyte telomere length (TL) after SARS-CoV-2 infection making it difficult to interpret whether shorter TL preceded infection or was due to higher white cell turnover in response to infection.

Added value of this study:

Our study is the largest study to date on the association of inter-individual variation in leucocyte telomere length with adverse outcomes from COVID-19 and the first to analyse telomere length that was measured prior to SARS-CoV-2 infection.

Implications of all the available evidence:

Our study suggests that independently of age, leucocyte telomere length is associated with greater risk of poor outcome from COVID-19, possibly through an effect on immune cell senescence, and that this explains some of the heterogeneity in inter-individual response to the infection.

Introduction

Older age has emerged as the most powerful risk factor for severe infection, requiring hospitalisation or critical care, and mortality from coronavirus disease 19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).^{1,2} One potential mediator of this effect is ageing of the immune system, leading to increased levels of proinflammatory senescent cells and reduced proliferative capacity of immune precursor cells.^{3,4} Telomere length (TL) is a key determinant of proliferative capacity and cellular lifespan, triggering senescence once a critically short TL is reached.⁵ TL – commonly measured in leucocytes (LTL) – shows a consistent negative association with age in cross sectional population cohorts and has previously been proposed as a marker of biological age for an individual. However, age only accounts for a small proportion of the substantial interindividual variation in LTL⁶ that exists at all ages, including birth.⁷ More recently, TL has also been proposed as a marker of replicative capacity and repair ability⁸, both of which, within the haematopoietic system, could potentially impair an individual's response to SARS-CoV-2 infection, above any effect of age.^{9,10}

A few small case-control studies, in which LTL was measured after SARS-CoV-2 infection at the time of hospital admission, have reported associations of shorter LTL with hospitalisation and severe outcomes.¹¹⁻¹³ However, their interpretation is complicated by the possibility that LTL measurements could have been influenced by white cell turnover in response to infection. To our knowledge, no study to date has reported on associations of prior (pre-infection) LTL values and adverse COVID-19 outcomes.

Here, we examine whether LTL measured several years prior to SARS-CoV-2 infection is associated with adverse COVID-19 outcomes, leveraging our recent completion of LTL

measurements in 474,074 participants aged 40-69 at time of recruitment into UK Biobank (UKB)⁶ between 2006 and 2010.^{14, 15}

Methods

Participants: Participants in UKB have been characterised in detail using questionnaires, physical measurements, urinary and plasma biomarker measurements, genomic assays and longitudinal linkage with multiple health record systems, including Hospital Episode Statistics (HES) and Office for National Statistics (ONS) mortality data.¹⁶ We have described the associations of inter-individual variation in LTL with multiple biomedical traits and risk of several diseases in UKB.¹⁵ Since the onset of the COVID-19 pandemic, UKB has also linked participants with results from clinically indicated SARS-CoV-2 testing and COVID-19 outcomes. By linking participants in UKB to SARS-CoV-2 testing datasets of Public Health England (PHE),¹⁷ we identified participants who tested positive between 16 March 2020 and 30 November 2020; the latter date corresponds to the latest release of HES data to UKB. We used HES records to identify SARS-CoV-2 positive participants who were admitted to hospital due to COVID-19 (ICD-10 code 'U07.1') within 28 days after a positive SARS-CoV-2 test. We further extracted information on need for critical care admission and respiratory support, due to COVID-19 (ICD-10 code 'U07.1'), via linkage to the ICNARC (Intensive Care National Audit and Research Centre) database, and deaths due to COVID-19 (ICD-10 code 'U07.1'), from the Office for National Statistics (ONS) death registry data.

The UK Biobank has ethical approval from the North West Centre for Research Ethics Committee (Application 11/NW/0382), which covers the UK. UK Biobank obtained informed

consent from all participants. Full details can be found at

https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics. The generation and use of the data presented in this paper was approved by the UK Biobank access committee under UK Biobank application number 6077.

LTL measurements: Full details of the LTL measurements in UKB are provided elsewhere.⁶ Briefly, LTL was measured using an established PCR method that expresses LTL as a ratio (T/S ratio).⁶ LTL measurements were adjusted for technical variation, log_e transformed and Z-standardised.⁶ In order to assess and adjust for within individual variability in LTL we measured LTL at two time-points (mean interval: 5·5 years) for 1,351 participants, yielding a regression-dilution ratio of ~0·68. Results in this study have been corrected for withinperson variability of LTL values over time (abbreviated "usual LTL"), as described previously.^{6,15}

Outcome definitions: Our study's primary outcome was a composite of COVID-19-related outcomes (ICD-10 code 'U07.1'): hospital admission, requirement for critical care, respiratory support, or mortality. We defined cases as those participants in UKB who tested positive for SARS-CoV-2 and had the primary outcome. For our primary outcome, controls were those who tested positive for SARS-CoV-2 but were not hospitalised within 28 days. To reduce the scope for collider bias¹⁸ we included only participants with positive SARS-CoV-2 tests done outside of hospital settings, since hospital admission itself may increase the likelihood of SARS-CoV-2 testing. The age, sex and ethnicity adjusted odds ratio (OR) for having a SARS-CoV-2 test (n=43,574) at any location, was 1.03, (95% CI 1.01-1.05; logistic regression P=1.0x10⁻⁴) per 1-SD shorter usual LTL.

We conducted several secondary analyses. First, we examined associations with each component of the primary composite endpoint. Second, we analysed the primary outcome using the rest of UKB participants as controls, as testing was unlikely to be random and the restriction to SARS-CoV-2 positive controls only is potentially subject to selection bias related to factors associated with infection.¹⁹ Third, to ensure that apparently post-COVID-19 outcomes were not re-admissions or influenced by proximate medical events prior to infection, we excluded participants with any hospital admission in the previous 6 months. Finally, we consider the impact of inflammation and baseline disease prevalence on LTL, to minimise the potential confounding from these factors on any LTL-COVID-19 outcomes relationship.

Statistical analysis: Univariable tests were performed using T-tests for continuous traits and Fishers exact or χ^2 tests for categorical traits as appropriate. Analyses involved multivariable logistic regression, adjusting for age (at SARS-CoV-2 positive test), sex and ethnicity. Due to small numbers, ethnic groups other than White were combined and participants with missing ethnicity (n=14 cases and 46 controls) were excluded. To remove the correlation between LTL and age, we used the residuals of LTL adjusted for age at baseline within the statistical models. In specific models to estimate the impact on the association due to inflammation or disease prevalence we re-estimated LTL residuals adjusting for age at baseline and C-reactive protein or any of 123 curated diseases¹⁵ (**Supplementary Table**) respectively. ORs were further adjusted for baseline smoking status and body-mass index (BMI) recorded at entry into UKB. Results are described as ORs associated with the outcome per one standard deviation (SD) shorter LTL residual, with associated 95% confidence intervals (CI) and p-values.

In an exploratory analysis, we conducted one-sample Mendelian randomisation (MR) analyses in UKB²⁰ to evaluate a causal relationship between shorter LTL and adverse COVID-19 outcomes, using the inverse-variance weighted (IVW)²¹ and weighted median²² methods with a set of 130 genome-wide significant (P<8.31x10⁻⁹), conditionally independent, uncorrelated and non-pleiotropic genetic variants we recently identified as genetic instruments for LTL.¹⁵ We used MR-Egger regression to assess robustness to horizontal pleiotropy.²³

Role of the funding body: The Funders had no role in study design, data collection, data analyses, interpretation, or writing of this study.

Results

By 30 November 2020, 914 participants were identified with an adverse COVID-19 related outcome and 5861 participants were identified as primary controls (positive community test for COVID-19 but not hospitalised). Their characteristics are summarised in **Table 1**. On average, compared to controls, cases were older and more likely to be male and from a non-White background. At time of their entry into UKB, they also had a higher BMI and more likely to be current smokers. (**Table 1**).

LTL at entry to UKB was on average shorter in cases compared with controls (**Table 1**). The OR for the primary outcome was 1.17 (95% CI 1.05-1.30; logistic regression P=0.004) per 1-SD shorter usual LTL, after adjustment for age, sex and ethnicity (**Table 2**). The OR only slightly attenuated after further adjustment for smoking status and BMI (OR=1.15, 1.03-1.28), and after adjustment for the presence of any of 123 diseases recorded at baseline (OR=1.14, 1.02-1.26), while adjusting for CRP slightly increased the estimated effect size (OR=1.19, 1.06-1.33). As expected, older age, male sex and non-White ethnicity were each

associated with higher risk of adverse COVID-19 outcomes independently of usual LTL (**Table 2**).

Sub-components of our study's primary composite outcome were not mutually exclusive, as 46 cases contributed to all four sub-components (**Figure 1**). Shorter usual LTL was significantly associated with higher risk of each sub-component (**Table 2**). ORs were broadly similar to the main findings in analyses that replaced the SARS-CoV-2-positive control group with all UKB participants as controls or that excluded any participant with a hospital admission in the six months prior to testing positive for SARS-CoV-2 (**Table 2**).

In MR analyses, the IVW odds ratio was 1·30 (0·85-2·00; MR-IVW P=0·224) per 1-SD shorter genetically-determined LTL, a non-significant result directionally concordant with the observational finding (**Table 2**). Results were similar using the weighted median method (**Table 2**) and there was no evidence of horizontal pleiotropy (MR-Egger intercept P=0·591).

Discussion

In a study of 6,775 participants with a positive test for SARS-CoV-2 (nested within the 500,000-participant UKB), we have shown that individuals with shorter LTL assessed several years *prior* to SARS-CoV-2 infection had higher risk of adverse COVID-19 outcomes, even after adjustment for several established risk factors for COVID-19 including age. This finding suggests that shorter LTL is likely to be independently associated with COVID-19 hospitalisation and severity. The results of analysis of LTL-associated genetic variants and COVID-19 were directionally concordant with our observational findings but non-significant. Our results, therefore, encourage further investigation of the potential causal relevance of TL to adverse COVID-19 outcomes.

The validity of our results is supported by several observations. First, our study found associations between older age, male sex, and non-White ethnicity that have previously been linked with adverse COVID-19 outcomes in the UK.² Each of these factors was associated much more strongly with COVID-19 outcomes than was shorter LTL. Second, we found significant associations of shorter LTL with each sub-component of our study's primary composite outcome. Third, our main findings persisted after adjustment for multiple risk factors. Fourth, our overall result was robust to sensitivity analyses designed to minimise the scope for potential biases. For example, collider bias can lead to false associations between a risk factor and an outcome,¹⁸ as highlighted by studies related to understanding of COVID-19 disease risk and severity.¹⁹ Indeed, we found evidence for potential colliders in our own analysis, observing a small but significant association between shorter LTL and higher likelihood of SARS-CoV-2 testing. Hence, we only included participants with a positive SARS-CoV-2 test outside the hospital setting, as hospitalisation itself may increase the likelihood of testing. Finally, considering the potential impact of inflammageing on the observed result we further adjusted for C-reactive protein and found no meaningful changes in the association.

The biological mechanisms through which shorter LTL might increase risk of adverse outcomes from SARS-CoV-2 infection remain to be clarified. Our finding that the association was not substantially attenuated when we adjusted for the association of LTL with multiple diseases at baseline, suggest that, if this association is causal, it is probably not simply a reflection of co-morbidity due to the impact of shorter LTL on risk of these diseases. A potential mechanism relates to the impact of telomere length dynamics on aging of the immune system²⁴ and the potential role of senescence in severe SARS-CoV-2 infection.^{3,4,25} While we have measured TL in leucocytes we believe these results likely reflects TL within T-

cells in this scenario, although further studies would be required to confirm this. When challenged with infection, individuals with shorter LTL prior to infection would potentially have less proliferative capacity within the T-cell population required for an efficient response to SARS-CoV2, coupled with reduced lymphopoiesis following infection.^{9,26} Individuals with shorter LTL may also potentially already harbour a higher proportion of senescent T-cells, reducing the number of functional cells that are able to respond to infection.²⁵ Additionally, senescent cells are known to adopt a pro-inflammatory phenotype, secreting high levels of cytokines, which can further drive inflammation in COVID-19 patients.²⁵ Our results are also in concordance with previous studies showing that shorter LTL increases the risk of adverse outcome in other infections.^{27,28}

Our study has several limitations. UKB is not representative of the general UK population; only 6% of those invited to participate did so.²⁹ The age distribution within UK Biobank includes participants aged 40-70 at baseline, who will be about 10-15 years older now, limiting the ability to assess association in individuals in other age groups. We were unable to fully assess ethnicity due to small numbers, though over time this limitation can be resolved with increased case numbers. Risk factor levels and mortality rates are lower than in the general population, although risk factor associations with mortality for a range of diseases are similar.³⁰ Hence, further studies are warranted in other populations. Our onesample Mendelian randomisation analysis in UKB had limited power to reliably estimate causal effects as fewer than one thousand participants had been hospitalised after a positive SARS-CoV-2 test and our genetic instrument of 130 variants, while using the most up to date information on LTL-associated variants, accounts for only ~4% of inter-individual variation in LTL.¹⁵ While there are data from large genetic studies of COVID-19³¹, they could not be used in our analysis because the outcome definitions differed substantially from

those we used, and because of their inclusion of within hospital testing that is potentially a collider with LTL and COVID-19 outcomes. Larger sample sizes with comparable disease phenotypes should, therefore, enable more precise evaluation of a potential causal association between shorter LTL and adverse COVID-19 outcomes.

In conclusion, in the largest study to date, we provide evidence that shorter LTL is associated with higher risk of adverse COVID-19 outcomes, independent of several major risk factors for COVID-19.

References

1. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ* 2020; **369**: m1966

2. Williamson EJ, Walker AJ, Bhaskaran K, *et al.* Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020; **584**: 430–436.

3. De Biasi S, Meschiari M, Gibellini L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. *Nature Comms*. 2020; **11**: 3434.

4. Akbar AN & Gilroy DW. Aging immunity may exacerbate COVID-19. Science 2020; **369**: 256–257.

5. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. *PNAS* 1992; **89**: 10114–10118.

6. Codd V, Denniff M, Swinfield C, et al. A major population resource of 474,074 participants in UK Biobank to investigate determinants and biomedical consequences of leukocyte telomere length. *MedRxiv.* 2021; https://doi.org/10.1101/2021.03.18.21253457

7. Factor-Litvak P, et al. Leukocyte Telomere Length in Newborns: Implications for the Role of Telomeres in Human Disease. *Pediatrics*. 2016; **137**. pii: e20153927.

8. Aviv A, Shay JW. Reflections on telomere dynamics and ageing-related diseases in humans. *Philos Trans R Soc B*. 2018;**373**.20160436 DOI: 10.1098/rstb.2016.0436

9. Aviv A. Telomeres and COVID-19. The FASEB Journal. 2020; 34: 7247-7252.

10. Tsilingiris D, Tentolouris A, Eleftheriadou I, Tentolouris N. Telomere length, epidemiology and pathogenesis of severe COVID-19. Eur J Clin Invest. 2020; **50:**e13376.

11. Sanchez-Vazquez R, Guío-Carrión A, Zapatero-Gaviria A, Martínez P, Blasco MA. Shorter telomere lengths in patients with severe COVID-19 disease. *Aging* 2021; **13**:1–15.

12. Benetos A, Lai TP, Toupance S, et al. The Nexus Between Telomere Length and Lymphocyte Count in Seniors Hospitalized With COVID-19. *The Journals of Gerontology: Series A*; 2021: glab026

13. Froidure A, Mahieu M, Hoton D, et al. Short telomeres increase the risk of severe COVID-19. Aging 2020; 12: 19911–19922.

14. Sudlow C, Gallacher J, Allen N, et al. UK Biobank : An Open Access Resource for
Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PloS Med.* 2015; 12: e1001779.

15. Codd V, Wang Q, Allara E, et al. Polygenic basis and biomedical consequences of telomere length variation. *MedRxiv* 2021; https://doi.org/10.1101/2021.03.18.21253457
16. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 2018; **562**: 203–209.

17. Armstrong J, Rudkin J, Allen N, et al. Dynamic linkage of COVID-19 test results between Public Health England's Second Generation Surveillance System and UK Biobank. *Microb Genom* 2020; **6**: mgen000397.

18. Cole SR, Platt RW, Schisterman EF, et al. Illustrating bias due to conditioning on a collider. *Int J. Epidemiol*. 2010; **39**: 417–20.

19. Griffith GJ, Morris TT, Tudball MJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. *Nature Comms*. 2020; **11**: 5749.

20. Minelli C, Del Greco MF, van der Plaat DA, Bowden J, Sheehan NA, Thompson J. The use of two-sample methods for Mendelian randomization analyses on single large datasets. *Int J Epidemiol.* 2021; **26**:dyab084. Epub ahead of print.

21. Burgess S, Butterworth A, Thompson S.G. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol*. 2013; **37**: 658–65.

22. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol*. 2016; **40**: 304–14 (2016).

23. Bowden J, Davey Smith G and Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*.
2015; 44: 512–25.

24. Moro-Garcia MA, Alonso Arias R, Lopez-Larrea C. Molecular mechanisms involved in the aging of the T cell immune response. Curr Genom. 2012; 13: 589–602 (2012).

25. Nehme J, Borghesan M, Mackedenski S, Bird TG, Demaria M. Cellular senescence as a potential mediator of COVID-19 severity in the elderly. *Aging Cell* 2020; **19**: e13237.

26. Bellon M. & Nicot C. Telomere Dynamics in Immune Senescence and Exhaustion Triggered by Chronic Viral Infection. *Viruses*. 2017; **9**: 289.

27. Gadalla SM, et al. Donor telomere length and causes of death after unrelated
hematopoietic cell transplantation in patients with marrow failure. *Blood.* 2018; 131:23932398.

28. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. *Lancet* 2003;**361**:393-395.

29. Fry A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. *Am J Epidemiol* 2017; **186**: 1026– 1034.

30. Batty GD, Gale CR, Kivimäki, M, Deary IJ, Bell S. Comparison of risk factor associations in

UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. *BMJ* 2020; 368:m131.

31. The COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur J Hum Genet* 2020; **28**: 715–718.

Data sharing

Source data is accessible via application to the UK Biobank.

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 6077 and was funded by the UK Medical Research Council (MRC), Biotechnology and Biological Sciences Research Council and British Heart Foundation (BHF) through MRC grant MR/M012816/1. C.P.N is funded by the BHF (SP/16/4/32697). V.C., C.M., V.B., Q.W., C.P.N. and N.J.S. are supported by the National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical Research Centre (BRC-1215-20010). Cambridge University investigators are supported by the B.H.F (RG/13/13/30194; RG/18/13/33946), Health Data Research UK, NIHR Cambridge Biomedical Research Centre (BRC-1215-20014), NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024) and MRC (MR/L003120/1). J.D. holds a BHF Personal Professorship and NIHR Senior Investigator Award. A.M.W. and E.A. received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart (11607). Z.R.E. is supported by BHF Clinical Research Training Fellowship No. FS/17/81/33318. S.E.P. acknowledges support from the NIHR Barts Biomedical Research Centre.

Author Contributions

V.C., C.P.N., J.N.D, S.E.P, N.C.H. and N.J.S conceived the project. All authors contributed to the sample definition and the analysis plan. Q.W., C.M. and C.P.N. performed the analyses. V.C., C.P.N., Q.W. and N.J.S. prepared the manuscript and all authors revised it. V.C., C.P.N., J.R.T., J.N.D. and N.J.S. (Principal investigator) secured funding and oversaw the project.

Competing Interests Declaration

The authors declare no competing interests.

Trait		Cases N=914	Controls N=5861	P-value
Age at COVID-19 test		70 (8.00)	64 (8.00)	1.85E-95
BMI		29.61 (5.39)	27.97 (4.86)	1.55E-20
Sex	Male	573 (62.69)	2675 (45.64)	
	Female	341 (37.31)	3186 (54.36)	8.20E-22
Ethnicity	Asian	33 (3.61)	217 (3.70)	
	Black	5 (0.55)	38 (0.65)	
	Chinese	3 (0.33)	9 (0.15)	
	Mixed	36 (3.94)	117 (2.00)	
	Other	8 (0.88)	78 (1.33)	
	White	829 (90.70)	5402 (92.17)	0.006
Smoking	Never	358 (39.43)	3236 (55.38)	
	Ex-smoker	408 (44.93)	2001 (34.25)	
	Current	142 (15.64)	606 (10.37)	1.27E-18
LTL (age adjusted)		-0.14 (0.97)	-0.03 (1.00)	0.002

Table 1. Characteristics of participants by case status.

Data shown are mean (SD) for continuous traits or n (%) for categorical traits. LTL, smoking status, BMI, sex and ethnicity are from baseline information. LTL is log-transformed and Z-standardised. P-values were obtained via t-tests for continuous traits, Ethnicity was assessed using Fishers exact test and other categorical traits were tested using a χ^2 test.

Table 2. Results of the main an	d secondary,	sensitivity analyses.
---------------------------------	--------------	-----------------------

	N cases	N controls	Odds Ratio (95%CI)	P-value
Composite outcome				
LTL (age-adjusted) (per 1 SD shorter)	914	5861	1.17 (1.05 , 1.30)	0.004
Age at COVID-19 test (per 5 yrs older)			1.58 (1.51 , 1.65)	<0.001
Sex (male vs female)			1.88 (1.62 , 2.19)	<0.001
Ethnicity (non-White vs White)			1.80 (1.39, 2.34)	<0.001
Separate components as outcome*				
Hospitalisation	672		1.17 (1.03 , 1.32)	0.013
Critical care support	383	5861	1.31 (1.12 , 1.53)	<0.001
Respiratory support	279		1.36 (1.13 , 1.64)	<0.001
Death	157		1.36 (1.07 , 1.72)	0.013
Population controls				
LTL (age-adjusted) (per 1 SD shorter)	914	465,946	1.19 (1.08 , 1.31)	<0.001
Excluding participants with recent hos	pitalisation			
LTL (age-adjusted) (per 1 SD shorter)	732	5861	1.15 (1.02, 1.30)	0.019
Mendelian Randomisation				
MR IVW	914	5861	1.30 (0.85 , 2.00)	0.224
MR-median			1.25 (0.62 , 2.50)	0.537

The main analysis is based on our composite outcome and the full multivariable model estimates are shown for each risk factor. *For each component of the composite outcome analysed separately, the results shown for these are labelled by outcome component but represent the LTL (age-adjusted) estimate (per 1 SD shorter). For each analysis, the numbers of cases and controls are given alongside the odds ratio, 95% confidence interval and Pvalue (from logistic regression models or MR). MR IVW: Mendelian randomisation inversevariance weighted method. MR-median: Mendelian randomisation weighted median method.

Figure 1. Venn diagram showing the distribution of the individual components of the primary outcome.



Where N is the frequency and: Hospitalised, due to COVID-19; Critical care admission, due to COVID-19; Respiratory Support needed, while in critical care due to COVID-19; Death due to COVID-19.

	Data for the CDVID-sample and	the entry LX Exclarit	gle callection that to callect are shown.		It was measured in. Prevalent cases are thus	rthat are identified to	a have accurred		
Disease category	Disease minune	tes qualite pres	Mittaniani U dati ana (N) para	K Bishash dini cara (N	UK Richark off operated	UK Balank KDD	TK Richards ICD9 miles	1K Bahash OPOsi coles	TX Risbark spreim min
Casar	- anar			24		-47 CN, C11, C12, C13, C13, C13,			
Casar	Erent		*1	10,038	(2001-102) Family only Boast same (2001-1002)	C71.3, C71.4, C71.3 C70, D89	178		
Canar	Certial		79	4,829	Carried same (2000-1012) or einjoursame sells servis (2000-1072) Large bored / solonatid sames, colors same /	CI1	140		
Canar	Colorada		54	2,993	(2000) [1020, 1022, 1023, 1021] Larvey/Ibrat uncer (2000) 2005, meetid	CISCI	195, 196,6-196,1		
					gland source (2000) 100 %, other solviney glass source (2000) 2014), by source (2000) 2010, browner concer (2000) 202113 mem source				
Canar	Head and weak		10	903	(2000) 2012), mosth annar (2000) 2077), tonil annar (2000) 2079), conference (2000) 2079),	CIL CH. CH CH	161, 140, 149		
					natal certity somer (2000-1007), sinn canor (2000-1009) amor of Ipimochipharyocies servity (2000-1004)				
Canar	Kidney		•	679	Kolosybund off same (2000-005) Leduamia (2000-004), ande replied	CH4, CH7, CH4	149		
Cana	Ladamia			708	Indiansia (2001-1074), disenio lymphospio (2000-1099) or disenio myskui (2000-1098) Lines / Instantioffelm serves (2000-1078)	CILCH	206.208		
Canar	Long			414	Long same, and cell or non-small sell long same (2001 (1001, 027, 1029), Age long	CII			
					ranar (ast mouthelisma) diagonal by dotte (22160 age) Lymphema (2000-1017), Hulphins.				
Canar	Lymphene		14	1,778	(2003-1052) or non-Biolgkim. Symptoma (2003-2017), andripte mysloma (2003-2017)	01108,010	280-201		Report of
Canar	Malanoma Onombasmal			3,719	Malignani molanoma (2001-2079) Omorthamid amort (2001-2017)	CEI	172		malignani melanama (20004-1393)
Canar	Ovary	r		904	Ovarian samon (2000) 3079/see falloptan tahu samar (2000) 3087) Paramar samar (2001) 4070	C34	140		
Canar	Prosisie Xanama	м	42	3,273	Male only. Provide senser (2001-1044) Kanoma (Bernamona (2001-1081) Kanifi inizzine (2001-2001-1083)	CHI CIP	143 171		
Casar	Xeal interior Xeenah		1	243	(2000-1019) Riemach anner (2000-1008)	C17 C16	110		
Canan Canan	Toyoid Tiyoid Unmo		1	7% 483 1,287	Testindar samer (2001-1047) Teynid samer (2001-1047) Uhrine'nskonsteld samer (2001-2003)	C11 C14C10	186 190 179, 182		
Cashroundar	And Dellates		-	1,217	Antic steamin (2002-1010) Atrid Buillation (2002-1071) or and Batter (2002-1087)	108	427.3		
					Heart attack / mysouriful infantion (20002-0079) Jourt attack disposed by a				Connery angioplasiy (PTCA) sizes (20004-1070),
Cashermodar	Conney alony drame		264	19,232	danter (H130.1), nye hant attack diagnoval (3350-apr), date of septemble inflation (12000-date), date of STTMI (12002-date), dat	0140	439-412, 414	KID-K40, K29, K20.1, K29	bypes guilt (CABC)
Cellerande	These Sections			1.144	within the state of the state o		~		(20064-1923)
					Bland presser multistices (0177-2, 6183-2), transfer / host publicss disperad by dote- hish bland second 1018-20 bish seconds.				
Cashermodar	Dyperion ics		811	N.417	Mani presser (87), astronated scaling (2003-140), high spatials 307, mesod scaling (77)-1401, high spatials 307, astronated	r 199413, 119	400-408		
					realing (4179-743), high districts 307, manual realing (91-793), age high blood pressure diagnosal (2788) age)				
Cashermodar	Pariphani saundar disaare		14	2,807	Pariphend vanisher discourt (P12) (2002-1007 or log daminution / internitioni classification (2002-1007)	173.4, IN	447.9, 444		
Cashermodar	Leynols		21	1,499	Reynold's please anno 1 disease (2002-1942) Noder (2002-1993), schendoroid	173.0	447		
					harmorthage (2002-2006), industria similar (2002-2007) vacualar hant problems diagnoral by dester - similar (0120-7), age	100.004, G20-3,			
Cashermodar	Xinda		128	8,187	sinke dagsmad (20% age), date of sinke (1200)-date), age of indusmis sinke (1200)-date), age of industries data	G84.6, G86.7, G86.7, G86.1	430-432		
					(1201.0-late), date of schwarbneid harmoning (1201.2-late)				
Caliconsis	Varianne		340	33,643	(2000-21HR)	83, 84	494		(20064.147%)
Cellenasla	Vanas dombambilum		220	13,018	palmonary ambedians (20002-2007) or damp tomous illumitania (EPVT) (20002-2000)	124, 96, 90, 90, 90, 174, 954, 974	415.1, 491.493		
Dignitur Dignitur	Abdominal Isonia Appendicities Contractioners		121	330 7,599	Abdominal Inexis (2002-1911) Appendiatio (2002-1912) Malaborption 1 andiae disease (2002-1436).	KIMER KIMER	10.10	798 100, 102, 101	
Digenitor	Colorand polyp		171	1.171	erollas disense reglatas sensitivity (21986-1) Rotal er orles admense / polyps (20002-100) or busign sceplanes	KK1.5, K62.6, K62.1, D12	3480, 211.3, 211.4, 2010	Built 1	
Dignitur	Diverticulation		290	11,227	Divertinder diverte / divertind its (20002-1498)	KH7, K78.2	842	812.1	Gallainea amarail
Dignitur	Californi Canite complegati telles due	-	13x	9,411 29,408	Christitianis / pill siene (2002-1107) Gaine unrephaged reflex or points reflex (2002-1120)	K21	774 739.11, 799.81	CDL G23	(20884-13/28)
Digenitor	Barmorducish		119	0,373	Hamomold. / pilm (20002-1909)	Ke4	430		Ham emiliationy / pilo surgery / handing of pilo
Dignitur	Hates havin		242	20,487	History Jameie (2000): 1474)	K44-0, K44-1, K44-7	112.3, 103.3, 101.3	cm	(20004-1400)
Digestros	Inflammatory bornel alcosure		72	8,008	Inflammatory Invest disease (2002-1001), Coded's disease (2002-1002) or identifier relatio (2002-1007)	639.631	335.536		
Dignitur Dignitur	legainal homin lexiable bernd symbome		183 239	13,279 13,419	Inguind Jumin (2000) 1111 Instable Incent spatiane (2000) 1110 Unit Advant (2000) 1110	K40 K28	3300, 3301, 3509 366.1	119,339,331	
Digesive	Linar stellarsis		34	1,723	billary vielesis (2002-1176), alaskelis livar disease or alaskelis vielesis (2002-1004) Developing (Januar anglesis)	676, 676	175		
Digestrue	Cheeplagiin Paurottin		22	1,011	(20002-1139) Parameters (20002-1045)	K35, K20.7 K35, K36.0 K36.1, K36.5, H25.2	870.00, 870.00 877.0-877.1-9723		
					Paptic silor (2002-100), dualend slave	826.5, 897.1			Popia dae sugary (2004-1766)
Digetive	Popile alear		101	9,404	(2003-1107) or pairie / stomath show. (2003-1142)	121123	332.333	600,682	Caninic alizer songray (20004-1767)
Digestrue	Partneritin		24	1,982	Particulus (2002-1290)	Kel, Kel, NYB, ADDI, ANDI, ATDI, ADDI, ANDI, ATDI	347, 34684, 00.46, 61263, 0932, 09884, 6147, 6147		
Digesitor	Undefined Institu		47	2,794	Undefined James (2000) 1912)	642	8811, 8821, 8831 288.81, 280-05, 788.11, 786.13	134,797	
							280.21, 280.25, 280.31, 280.35, 380.41, 380.45		
Enloying	Type I dishsten		33	2,369	Diabatas, type I (percelle type) (20002-1222)	110	238.31, 286.35, 238.81, 280.45, 280.71, 280.75		
							2 No. 81, 2No. 83, 2 No. 91, 2No. 90 3 No. 90, 201, 47, 780, 1		
					Dialosia, type II (20012-1227), genetic dialosie		0.280 12.280 20.281 22.290 30.290 31.2		
Endourine	Type 2 dishster		338	22,481	(2003) 1229) and age of small 32+ years old (2026-510)	811, 813,814	30.40,200.42,200.00 200.32,200.40,200 42,200.70,200.72,20		
Interim	Deseriousidae			4.327	Downlowidow / Americalizatio (2002-1225	1 201	0.86,293.81,296.90, 293.82 262.9		
Endorine Gastroniney	Dyperkynsidion Ranige brand kemp		339 41	23,840	Hypothymialum / myscoalema (2000-1226) Famile only: Boast barry (2002-1666)	201.9 D24, NHER, NHEP	246.9 217, 4308, 4309		
Gastroniaary	Emige presiate hyperplana	м	121	10,647	Maleonly. Eslarged provisis (2000:1396) or basign provisis hypertophy (BPR) (2000:1316)	Nati	030		
Gastroniany	Bonni eysi	r	73	7,699	Famile only. Beam spin (2002-1267)	700.0700.0	423.0-423.4		Broast syst / absame removal (20004-1912)
Contractory	Chemic kidney drame			1,308	Event / kidney kilow(2002 1192) separate dialysis (2002 1193) or not requiring dialysis (2002 1194)	NIX	240	$\begin{array}{l} 1.76.6, MH1.4, MH2.5, MH2.5, MH2.4, MH2.4, MH2.4, MH2.6, MH2.7, MH2.6, \\ MH7.4, MH7.4, MH7.6, MH7.6, XH1.2, XH2.5, XH1.5, XH1.6, XH1.1, XH1.2, XH2.1 \\ \end{array}$	
Cashoology Cashoology	Endometricsis Fonale indetility	1	7	6,825	Family and Family Endometrics (2002-1402) Family and Family (2002-1402)	NRO NRTO	617 628		Provinceso / com
Cashnoisary	Kidney stone		112	6,824	Exiliary stone / unite stone / Makile stone (20002-1197)	ND6-9-ND6-8, N21, N22, N13-2	HCLHCAH	MIR 4, M251, M261, M262, M263, M271, M272, M273, M274, M281, M281, M281, M281, M281, M281, M281, M281, M281, M211, M213, M213, M214, M281, M214,	kähey sine segery / hiksiopy (2008-1197)
Contractory	Oraniae spot	r	201	11,912	Familicosly. Ovarian syst or opin. (20002-13.0%) polyopsia evanian./ polyopsia: evanian symbosse.(20002-13.00)	NR3-0-NR3-2, 8282, 027	629.8-629.3, 2964	diurt dawa	Ovarian opsi samoral / sargary (20084-1308)
Gastroniany	Unite Iberial	r	218	10.114	Familie only. Unitiae Elevisis (20002-1311)	021	218		Mycmatumy / fibrails emerced (2004.1309)
Gastraniaary	Uneine pulyps	r	124	9,829	Panaleonly. Uniterpolyge (2002-1332)	NR4-0, NR4-1, EDB	6210, 2196, 2191		Unrise polypostomy lateriae polyps measured
Gastraniaary	Unios podapar	r	147	9,013	Familieanly, Vaginal prolapse / station prolapse (20004-1333)	N81	425.0-425.4, 418.4- 425.9		(20884-1839)
Instance	Allery hypersensitivity		244	10.721	Allargy / https://aughtplanix (2002-1770)	178.1, 178.4, 1783 1781, 29101, 29102, 1888, 208,	990.6, 51381, 9934, 997, 99827, 52386,		
Immune	Angle demation		200	13,874		27100.27100	4400, 4100		
Immune						K2833 1.20	675.8		
among the second	Immunolificancy			744	Kell reported losings of innersecolulizioncies, HYP ADR (2000) 1479)	K2003 120 200-206, 820-824, 875, 221	676.8 67963, 2796, 2791, 2790, 2793, 79873, 642, YES		
Instant	Internatiofationsy Rysionic logue arythematous Polymysigin domination Pontasis		11 12 13	754 754 1,090 6,291	Infilippeted losiery of intermetedelosevies, HEVARIE (2002-1479) Epistenic lopus explanations (2002-1311) Polympilgis domention (2002-1377) Portanic (2002-147)	82833 120 280-286, 820-824, 875, 221 MIT, 80512, 109 MIT, 8, MIT, 5 L40	695.8 67963, 2796, 2795, 2795, 2793, 79075, 645, 958 735.6, 37334, 6934 729 696		
loomaa loomaa loomaa	lonnancializioney Rycinnic lopes arythematoan Polyorysigis domination Postanis Ramatinis Ripgoni's syndrome		1 1 1 1 1 1 1 1	NA 701 1,090 6,091 1,077 399	Rel Imported Voising of Immunolohismuin, IMPURATE (2000) 5199 Episante Inport optimisation (2002 2001) Polycopidge Amantian (2002 2017) Postelani (2002 2017) Essentiani (2000 1171) Epispen Spalemui / sian spalemui (2002 1192)	62003 120 Disto Disk, 820-824, 875, 223 Milli, 80112, 109 Milli, 80113, 109 Disk Milli, 9	491.8 67903, 2798, 2791, 2790, 2793, 79071, 647, 798 670, 7158, 4994 728 699 139 739.2		
	Innearciellationsy Nytientis lapus orythemations Polytopidgia dammation Postania Annealistis Nytopina's syndrome Haliserbator pyloni		13 13 10 10 10 10 10 10 10 10 10 10 10 10 10	765 705 1,000 6,011 1,017 309 1,314	Kell separtal kining af innermedielismin, HEV:ARM (2000-1479) Exploratio lapore echamismic (2000-1371) Polympilip disensities (2000-1377) Polympilip disensities (2000-1377) Farminis (2000-1387) Espandris (2000-1371) Espandris (2000-1371) Espandris (2000-1371) Espandris (2000-1371) Refl separtel (2000-1372) Refl separtel (2000-1372) Refl separtel (2000-1372)	8283 120 2000, 820, 820, 824 825, 223 MCL, 80112, 149 MCL, 80112, 149 MCL, 80113, 149 MCL, 80113, 149 MCL, 80 80 MCL, 80 80 80 80 80 80 80 80 80 80 80 80 80 8	495.8 4790.3 2796, 2796, 2795, 4270.2 2996, 2795, 402, 918 719.8, 37334, 4994 729 409 139 719.2 41.00		
lanaar lanaar lanaar lanaar lahatan	Innumerielleinney Rycinnis Japan seydomatous Pedrosolgie domantos Pedrosolgies Ramolinis Reparato spatemer Helischator pyloti Dispatitis		13 13 13 14 14 23 29	344 784 1,490 1,497 1,497 1,394 2,493	Liff appried (sincey of incremendellinewise, DTLEARC (2000) Life() Falpenties (spece Sciences) (2000) Life() Falpenties (2000) Life() Falpenties (2000) Life() Faunciano (2000) Life() Fallenhauer generation (2000) Life() Kallenhauer (2000) Life()	12833 129 129 129 129 129 129 129 129 120 120 120 120 120 120 120 120 120 120	495.8 47963, 2796, 2796, 2796, 2796, 2796, 2796, 2796, 2796, 2706, 2716, 8, 9716, 9716, 27		
laman laman laman laman lahatan lahatan lahatan	Innernalificancy Rysientis Japa arglaendatus Paratas Paratas Ramatasis Ramatasis Ramatasis Ramatasis Ramatasis Ramatasis Ramatasis Ramatasis Ramatasis		11 11 12 14 14 21 24 21 24 24 24 24 24 24 24 24 24 24 24 24 24	NH 201 4,001 1,000 1,001 1,001 1,001 2,001 7,00 7,000 7,000	Erf opport Josep of second-distance, 1971 IAM (2005) 34400 Herr LAND (2005) 34400 Herr Landon, 2006 IAM (2005) 1007 Provins (2006) 34501 Herr Landon, 2006 IAM (2006) 1007 Herr Landon, 2006 IAM (2006) 1007 Madan, 2006 IAM (2006) IAM (200	2003 128 2080266, 825-824, 875, 221 862, 8012, 181 863, 8013, 181 208 863, 8013 1864 1864 1864 1864 1864 1864 1864 1864	485.8 4788,2788,2788,2783,482 482,788,2783,4834 7284,37234,4834 728 4138 4138 4138 4138 4138 4138 4138 413		
lanar lanar lanar lanar lahina lahina lahina lahina lahina	Innenolefismey Rysienis Japa arglemation Paratas Ramitas Risantas Ripark spilone Bilimbase pylot Bigatiti Malaria Malaria Mangin Mangin		11 11 10 10 11 10 11 10 10 10 10 10 10 1	NA 311 1,000 4,001 1,007 1,009 1,004 2,003 7,00 2,003 1,007	Alfragencia de la construcción d	20031 128 128 128 128,086,823,824,824,823 825,0824,823 128,084,823 128,084128,084 128,084 128,084128,084 128,084 128,084128,084 128,084128,084 128,084128,084 128,084120	494.8 (998), 2798, 7998, 7998, 7998, 7998, 7998, 7997, 645, 9998 (7198, 7108, 7198, 7108,		
Inner Inner Inner Inner Inner Inner Inner Inner Inner Inner Inner Inner Inner	Insurantificancy Springin Spring Sphonistem Polycopics Anomatics Polycopic Sphonistem Standardson Bilandardson Bilandardson Managino Managino Managino Managino Managino Managino Managino Managino Managino Pomania Itani		13 14 15 16 17 17 17 17 17 17 17 17 17 17	N4 28 1,80 6,31 1,87 3,99 1,34 2,83 2,83 2,83 1,34 2,83 1,34 4,460 1,89 1,89	Jelf grand Johnson J. Hanna and Antonia Hanna Markan (2014) (2014) Hanna Markan (2014) (2014) Hanna Markan (2014) Hanna (2014) (2014) Hanna (2014) (2014) Hanna (2014) (2014) Hanna (2014) (2014) Hanna (2014) (2014) (2014) (2014) Hanna (2014) (2014) (2014) (2014) Hanna (2014) (2014) (2014) (2014) (2014) (2014) Hanna (2014) (2014	2003 128 228 228 228 228 228 227 227 227 227 2	04.8 (0783, 2784,		
Interes Interes Interes Interes Interes Interes Interes Interes Interes Interes Interes Interes Interes Interes	Jonamabilangy Jopinsi Japa sphankam Alyngipa kanania Faunia Kanalia Balanka Balanka Masha Masha Mangin Mangin Mangu Mang		13 13 14 14 15 16 17 17 18 17 18 18 18 18 18 18 18 18 18 18	N4 201 1,000 0,011 1,077 2,033 2,033 2,033 705 2,033 1,044 1,044 2,044 1,079	1419 graph (Jung) 44 menutokina), 1429 graph (Jung) 44 menutokina), 147 menutoking (Jung) 45 menutoking 147 menutoking (Jung) 45 menutoking 147 menutoking (Jung) 45 menutoking 148 menutoking (Jung) 45 menutoking 149 menu	E200 200 200 200 200 200 200 200	64.8 05%, 23%, 23%, 23%, 25%, 23%, 25%, 25%, 25%, 25%, 25%, 25%, 25%, 25		
Inner Inner Inner Inner Inner Interne Interne Interne Interne Interne Interne Interne Interne Interne Interne	Innemationary Sylvenis Representation Polycepite Atomation Polycepite Atomation Examines Examines Reports Repo		11 13 14 14 14 14 15 16 16 16 16 16 16 16 16 16 16	N4 28 1,000 1,001 1,007 89 1,014 2,023 1,014 1,017 4,440 1,017 4,440 1,017 4,440 1,019 1,017 4,040 2,014 2,014 1,017 4,040 2,015 1,017 1,01	14 Segurity of Lange of L	EXERT 25 C 25	462.8 (958), 2596, 25977, 2597, 2597, 2597, 2597, 2597, 2597, 2597, 2597, 2597, 2597		
Inner Inner Inner Inner Inner Inferien Inferien Inferien Inferien Inferien Inferien Inferien Inferien Inferien Inferien Inferien Inferien Inferien Inferien	kanamakanya Kayinni kupa sehankian Papangi a hanakian Panangi Kanakia Kanakia Kanakia Mangi Mangu Mang		11 11 11 11 11 12 12 12 12 12	N4 201 1,000 1,000 1,000 1,000 2,001 2,003 2,003 2,003 2,003 1,000	Jal agrand Long Y Linux Additional, Bernach State (2016) 2017 Arganic Space State (2017) Arganic Space	EXERT Sectors	467.4 (963,2796,2796,2797,2797,2797,2797,2797,2797		
Ionee Ionee	Jamming Manager Appropriate American Properties Services Approximation A		11 11 11 11 11 11 11 11 11 11	N41 301 1,000 4,001 1,077 309 1,304 2,003 1,304 2,003 1,077 4,460 1,079 2,054 9,317 7,088	Margan de la construit de la c	Exert 2013 2015 2015 2015 2015 2015 2015 2015 2015	49.4 (99.1, 294, 294, 294, 294, 294, 294, 294, 294		
longe longe	kanamakanya Kapisani kapa sapahankan Pelapanjakan Sapata S		11 11 12 13 14 14 21 29 27 86 40 10 10 12 23 23 23 23 23 23 23 23 23 2	N4 20 1,000 1,001 1,001 1,001 2,003 2,003 2,003 2,003 2,003 1,004 2,003 1,004 2,003 1,004 2,003 1,004 2,003 1,004 2,003 1,004 2,003 2,004 2,004 2,004 2,005 2	And and an and a manufactures of the sector	KARAT BADATA BADATA SALANA SAL	497.4 (998.2)986,2986,2986,2986,2986,2986,2986,2986,2		
Imme Imme Imme Imme Interne In	Jacumindum Serian Super grindum Perspective Series		11 12 13 14 14 14 14 14 14 14 14 14 14	344 356 4.000 4.001 389 1.044 2.033 2.033 2.033 2.033 2.033 2.033 2.033 2.033 2.033 2.0344 2.034 2.03444 2.03444 2.03	And Stand and American America	LEUR DESCRIPTION D	47.4 (************************************		
long lange l	Jacamidadi Cancin Speer generation Sector Speer generation Sector Speer generation Speer ge		11 12 13 14 14 14 14 14 15 16 17 18 18 19 19 19 10 10 10 10 10 10 10 10 10 10	344 394 4,000 4,000 1,000 2,00	And Angene and Annue Ann	LEURI DE CONTRESS DES AUTORNALS DES AUTORNALS DES AUTORNALS DE CONTRESS DE CON	47.4. (1994, 2294, 1994, 2294, 1994, 2294, 1995, 2293, 1995, 2293, 1995, 2293, 1995, 2293, 22944, 22944, 2294, 2294, 2294, 2294, 2294, 2294, 2294, 2294, 229		
long lange l	Jacamidadi Sector Super generalization Sector Super Sector Super Sector Super Sector S		10 11 10 10 11 12 14 14 15 16 17 16 16 16 16 16 16 16 16 16 16	344 394 4,010 1,000 4,010 1,000 2,013 2,013 2,013 2,013 2,013 2,013 2,013 2,013 2,014 2,0,	And experimental and a second	Louis Louis 105, 205, 2011, 2014 105, 2014, 2014, 2014 105, 2014, 2014, 2014 105, 2014, 2014 105, 2014, 2014 105,	46.4. 46		
konser konser konser konser konser konsen ko	Jamin Speeg majer Speeg Speeg majer Speeg S		10 11 10 10 11 12 14 15 15 15 15 15 15 15 15 15 15	144 756 4.211 2400 2427 2401 2401 2401 2401 2401 2401 2401 2401	And Segment and Security Secur		44.5.1 (1998.) 2785. 1997. 2795. 2795. 2797. 1997. 2797. 2797. 2797. 46.8 (1997.) 2797. 47.8 (2997.) 2797. 47.8 (2997.) 2797. 47.8 (2997.) 2797. 38.8 (2997.) 2797. 39.8 (2997.) 2797. 30.8 (2997.) 2		
lanar la	Jeansfard Manapare fauthority Manapare fauthority Manapare Man		0 11 12 13 14 15 15 15 15 15 15 15 15 15 15	144 316 1480 4.211 2.012 3.02	And expertence of a second sec	Exercise Exerci	44.3.4. (1994).2196. 46.2. (1994).2196. 46.2. (1994).2196. 46.2. (1994).2196. 46.2. (1994).2196. 47.2. (1994).2196. 47.2		
lange lange	Jeansfurgeregenerations Antipage Sections Antipage Sections Antipag		0 11 12 13 14 14 15 15 15 15 15 15 15 15 15 15	144 354 440 440 317 318 318 2433 758 7,220 2433 7,220 2434 2,343 1,397 7,220 1,297 7,210 1,077 7,210 1,079	 Managama and Managama and Manag	Laure La	49.4 49.4		
kanan kan k	Jenninger Jenninger Marken		0 10 10 10 10 10 10 10 10 10 1	144 786 4001 4001 4001 100 100 100 700 700 700 700 700 700	 Martine Martine M				
landson landso	Jaman Berger Stand			MI NI	 Managaman Bang, Sang Sang Sang Sang Sang Sang Sang Sang				
	Kanadiana Sanada			MI 30(30() 1001 1001 1001 1001 1001 1001 1001 1	 Mantana M		441 441 441 441 441 441 441 441		
				MI 31(100) 1000 1000 1000 1000 1000 1000 10	 Managama and Managama and Manag		1441 1442 1442 14444 1444 1444 1444 1444 1444 1444 1444 1444 1444 1444		
	Kanada Ka			MA 3.1.1 1.427 1.427 1.428 2.431 1.427 2.431 2.441	 Managaman and Angel Ang				
	Amantana ang ang ang ang ang ang ang ang ang			MB 34.000 34.000 1.077 2.040 2					
	Amenina and a second and a seco			MA 1.00 1.	Markan San San San San San San San San San S				
				ык 100 100 100 100 100 100 100 10	 Martine and an an				
	American and a second and a sec			444 140 140 140 140 140 140 140	 Alexan and an and an an				
	 Second Second Sec			444 140 140 140 140 140 140 140	 Martine Standards and Standards				
				444 140 140 140 140 140 140 140		And Series and Series			
				444, 1,2,2,2,4,4,4,4,4,4,4,4,4,4,4,4,4,4,4,4,		Hanni and an			
				444. 144.	 Anstructure and an an and an an and an an and an an an and an and	Hanni and an			
	Anterior and anterior anterio anterior anterior anterior anterior anterior			444 345 346 346 346 346 346 346 346 346	Anderson and and and and and and and and and an	And Series and Series			
				444 345 346 346 346 347 348 348 348 348 348 348 348 348	Anderson and and and and and and and and and an	And Second S			
				444, 345, 346,		And Series and Series			
				444 345 346 2407 240	Anderson and and and and and and and and and an	And Series and Series			
	Jone See See See See See See See See See S			444 31 31 31 32 34 34 34 34 34 34 34 34 34 34		Hamilton and an and an	Martin and a second a secon		
	amenoperators and a second and			444 3 3 3 3 3 3 3 3 3 3 3 3 3		And Series and Series			
	 Control of the sector of the se			446 35 36 36 36 36 36 36 36 36 36 36	Anderson and and and and and and and and and an	And Series and and Series an	and manufactures and ma		
	 Second Second Sec			444 345 345 345 345 345 345 345	Anstructures and an anstructure and an anstructure and an	And Series and a series and a			Nag definitions *
	 Control of the sector of the se			446 340 340 340 340 340 340 340 340		Barti Status Sta			Net data sense *
	 Accession of a constraint of a co			446 340 340 340 340 340 340 340 340	Anderson and and and and and and and and and an	And Series and	Alight and a start of a start		
	amente a la conservación de la c			446 34 34 34 34 34 34 34 34 34 34		And Series and and Series and			
	 Control of the sector of the se					Component Component <t< td=""><td></td><td></td><td>Part of the second second</td></t<>			Part of the second
	 Sector Sector Sec			445 34 34 34 34 34 34 34 34 34 34	Handbardensensense Andersensensense Andersensensense Andersensensense Andersensensense Andersensensense Andersensensensense Andersensensensense Andersensensensensense Andersensensensense Andersensensensensensensense Andersensensensensensensensensensensensensens	Ame in a serie of a se			Nagi giga ange i
	amente a la conservación de la c					Barti Company C			